期刊文献+

抗HPV生物蛋白敷料对LEEP术后持续HR-HPV感染的临床观察 被引量:3

Clinical observation of anti-HPV biological protein dressing for continuous HR-HPV infection after LEEP
下载PDF
导出
摘要 目的分析抗HPV生物蛋白敷料对LEEP术后持续HR-HPV感染的临床效果。方法选取2016年1月~2018年1月期间在某院治疗的90例LEEP术后持续HR-HPV感染患者,随机分成两组,观察组(术后给予抗HPV生物蛋白敷料,n=45)和对照组(术后未采用任何药物进行治疗和干预,n=45),对比两组患者临床效果。结果随访1年,观察组术后3个月(71.11%)、6个月(60.00%)、9个月(42.22%)、12个月(17.78%)HPV阳性率明显低于对照组(88.89%、80.00%、66.67%、40.00%),两组数据对比差异明显(P<0.05);观察组患者术后6个月、9个月、12个月HPV-DNA负荷量明显降低,与对照组相比差异具有统计学意义(P<0.05)。结论LEEP术后持续HR-HPV感染患者给予抗HPV生物蛋白敷料治疗,可降低HR-HPV持续感染风险,临床效果显著。 Objective To analyze the clinical effect of anti-HPV bioprotein dressing on continuous HR-HPV infection after LEEP.Methods A total of 90 patients with HR-HPV infection who underwent LEEP in our hospital from January 2016 to January 2018 were randomly divided into 2 groups.The observation group(postoperative anti-HPV biological protein dressing,n=45)The control group and the control group(no treatment or intervention with any drugs,n=45),compared the clinical effects of the two groups.Results One year follow-up,the positive rate of HPV in the observation group was significantly lower than that of the control group at 3 months(71.11%),6 months(60.00%),9 months(42.22%),and 12 months(17.78%)(88.89).%,80.00%,66.67%,40.00%,the difference of data between the two groups was significant(P<0.05);the HPV-DNA load of the observation group was significantly decreased at 6 months,9 months and 12 months after operation,and the control The difference between the groups was statistically significant(P<0.05).Conclusion Patients with persistent HR-HPV infection after LEEP can be treated with anti-HPV biological protein dressing,which can reduce the risk of persistent infection of HR-HPV.The clinical effect is significant.
作者 李秘 纪燕琴 LI Mi;JI Yan-qin(Department of Gynecology and Obstetrics,Huizhou Central People's Hospital,Huizhou 516000,China)
出处 《中国处方药》 2020年第3期164-165,共2页 Journal of China Prescription Drug
基金 惠州市科技计划项目(190415104573005)。
关键词 抗HPV生物蛋白敷料 LEEP术 HR-HPV持续感染 Anti-HPV biological protein dressing LEEP HR-HPV persistent infection
  • 相关文献

参考文献11

二级参考文献137

  • 1肖松舒,范洁琳,贺斯黎,于科楠,邓新粮,薛敏.16320例妇科门诊患者HPV感染情况分析[J].中南大学学报(医学版),2015,40(4):373-379. 被引量:25
  • 2Katki HA, Schiffman M, Castle PE, et al. Benchmarking CIN3 + risk as the basis for incorporating HPV and Pap cotesting into cervical screening and management guidelines [J]. J Low Genit Tract Dis, 2013, 17 (5 Suppl 1) : $28-35. DOI: 10.1097/ LGT.0b013e318285423c.
  • 3Saslow D, Solomon D, Lawson HW, et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer [J]. CA Cancer J Clin, 2012, 62 (3) .. 147-172. DOI : 10.3322/caac.21139.
  • 4Massad LS, Einstein MH, Huh WK, et al. 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors [ J ] Obstet Gynecol, 2013,121(4) :829-846. DOI: 10.1097/AOG. 0b013e3182883a34.
  • 5Gage JC, Katki HA, Schiffman M, et al. The low risk of precancer after a screening result of human papillomavirus- negative/atypical squamous cells of undetermined significance papanicolaou and implications for clinical management [J]. Cancer Cytopathol, 2014, 122 (11) : 842-850. DOI: 10.1002/ cncv.21463.
  • 6Zhao FH, Lin M J, Chen F, et al. Performance of high-risk human papillomavirus DNA testing as a primary screen for cervical cancer: a pooled analysis of individual patient data from 17 population-based studies from China[J]. Lancet Oncol, 2010, 11 (12) : 1160-1171. DOI: 10.1016/S1470-2045( 10)70256-4.
  • 7Schiffman M, Vaughan LM, Raine-Bennett TR, et al. A study of HPV typing for the management of HPV-positive ASC-US cervical cytologic results [J]. Gynecol Oncol, 2015, 138 (3): 573-578. DOI: 10.1016/j.ygyno.2015.06.040.
  • 8Katki HA, Kinney WK, Fetterman B, et al. Cervical cancer risk for women undergoing concurrent testing for human papillomavims and cervical cytology : a population-based study in routine clinical practice [ J J. Lancet Oncol, 2011,12 (7) : 663-672. DOI : 10.1016/ S1470- 2045( 11 )70145-0.
  • 9Katki HA, Schiffman M, Castle PE, et al. Five-year risk of CIN3 + and cervical cancer for women with HPV testing of ASC-US Pap results [J ] . J Low Genit Tract Dis , 2013 , 17 ( 5 Suppl 1 ) : $36-42. DO1 : 10.1097/LGT.0b013e3182854253.
  • 10Combes JD, Guan P, Franceschi S, et al. Judging the carcinogenicity of rare human papillomavirus types [J]. Int J Cancer,2015,136(3 ) :740-742. DOI: 10.1002/ijc.29019.

共引文献214

同被引文献24

引证文献3

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部